title: Bulbocavernosus reflex testing: a preliminary study on the prognostic factors for potency and response to sildenafil citrate after bilateral nerve-sparing radical prostatectomy.
abstract: OBJECTIVE
  Erectile dysfunction (ED) following radical prostatectomy is of major concern for both patients and caring physicians. We evaluated the bulbocavernosus reflex latency (BCRL) and amplitude (BCRA) following bilateral nerve-sparing radical retropubic prostatectomy (NS-RRP) to predict the response to sildenafil citrate (SC).
  
  
  METHODS
  Patients were recruited in our ED clinic following NS-RRP. Exclusion criteria included preoperative significant ED, neurological disease, and nitrates treatment. Patients were defined as non-responders only after four consecutive unsuccessful trials of 100 mg SC.
  
  
  RESULTS
  Twenty patients at least 3 months after surgery were included in this study. Five patients (25%) regained spontaneous erections, although insufficient for vaginal penetration. All of them had normal BCRL and normal BCRA as well as good response to 100 mg SC. Three patients (15%) lacked spontaneous erections and had prolonged BCRL with normal BCRA. This subgroup eventually regained erections using SC. Twelve patients (60%) lacked spontaneous erections and had prolonged BCRL and low BCRA. They failed SC trials and achieved erections using intra-cavernosal injections (ICI) of 10 microg PGE(1).
  
  
  CONCLUSIONS
  Neurophysiologic evaluation consisting of BCRL and BCRA was found to be useful in the prediction of the response to SC following bilateral NS-RRP. Patients who do not regain an erection, and have abnormal BCRL and BCRA 6 months after surgery, will probably be SC non-responders and may benefit from ICI. A subset of patients with preserved BCRA and prolonged latencies has been shown to have a better chance to respond to SC.
authors.affiliation: Petach Tikva Andrology Practice, 1 Rishon Lezion St., Petach Tikva, 49723, Israel. dr.andrology@gmail.com
authors.forename: Shai
authors.initials: S
authors.lastname: Shefi
authors.forename: Manuel
authors.initials: M
authors.lastname: Zwecker
authors.forename: Jehonathan H
authors.initials: JH
authors.lastname: Pinthus
authors.forename: Yoram
authors.initials: Y
authors.lastname: Mor
authors.forename: Gabriel
authors.initials: G
authors.lastname: Zeilig
authors.forename: Yeheskell
authors.initials: Y
authors.lastname: Shemesh
authors.forename: Jacob I
authors.initials: JI
authors.lastname: Hanani
authors.forename: Gil
authors.initials: G
authors.lastname: Raviv
mesh_terms: D000368:Aged; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D011467:Prostate / Q000294:innervation*; D011468:Prostatectomy / Q000009:adverse effects / Q000379:methods*; D011687:Purines / Q000627:therapeutic use; D012021:Reflex, Abnormal; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use*
chemical_list: D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate